BostonGene and ImmunoGenesis Announce Strategic Partnership to Overcome Immunotherapy Resistance.

BostonGene is the developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, also announced a strategic partnership to accelerate the clinical development of the company’s lead program. 

IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2, and is being studied in a phase 1a/b dose-escalation and dose-expansion safety and efficacy trial (NCT06014502) in patients with solid tumors that have failed to respond to standard of care therapies.  

In collaboration with IMGS-001, it can help identify those patients most likely to respond to treatment based on each patient’s comprehensive immune and genetic profile. 

According to Towards Healthcare, the immune checkpoint inhibitors market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 65.09 billion in 2026 to approximately USD 164.34 billion by 2035, representing a compound annual growth rate (CAGR) of 10.84% from 2026 to 2035. Growth is driven by the rising prevalence of cancer, and the global burden of cancer has been increasing, leading to a higher demand for effective cancer treatments. With a growing shift toward immunotherapy as a standard of care in oncology. 

About BostonGene Corporation

The company is focused on revolutionising cancer treatment through AI-powered molecular and immune profiling. It aims to provide personalised therapy solutions for patients. It redefines cancer patient care and drug development through the integration of data and artificial intelligence. It utilises AI-driven solutions to analyse molecular profiles of tumors and immune systems, enabling clinicians to make informed treatment decisions.

BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights.

These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimise therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation.

The company is developing a multi-mechanism strategy aimed at addressing the pathology of immune-excluded tumors by overcoming the immune exclusion to enable an immune response in the tumor microenvironment.  

A recent report by Towards Healthcare highlights that the immune checkpoint inhibitors market is witnessing growth due to the demand for scalable customer support solutions, continuous user interaction, and rising awareness of mental wellness. Advancements in machine learning, natural language processing, and emotional identification are improving the quality of interactions, boosting consumer acceptability and trust.